Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Jun 25:63:34-37.
doi: 10.1016/j.jdcr.2025.06.022. eCollection 2025 Sep.

Recalcitrant epidermolysis bullosa acquisita treated with upadacitinib as a bridge to rituximab

Taha Rasul  1 , Anthony Concilla  1 , Michelle Militello  1 , Paola Torres  1 , Angelia Stepien  1
Affiliations
Case Reports

Recalcitrant epidermolysis bullosa acquisita treated with upadacitinib as a bridge to rituximab

Taha Rasul et al. JAAD Case Rep. .
No abstract available

Keywords: JAK inhibitors; autoimmune blistering disease; bridging therapy; epidermolysis bullosa acquisita; mechanobullous EBA; refractory dermatologic disease; rituximab; upadacitinib.

PubMed Disclaimer

Conflict of interest statement

None disclosed.

Figures

Fig 1
Fig 1
Initial presentation of extensive tense bullae, erosions, and crusting predominantly affecting the breasts (A) and extremities (B), consistent with mechanobullous EBA. EBA, Epidermolysis bullosa acquisita.
Fig 2
Fig 2
A and B, Marked improvement of skin lesions following initiation of upadacitinib and subsequent rituximab therapy, with resolution of erosions. Postinflammatory hyperpigmentation and milia at sites of scarring can be seen.
See this image and copyright information in PMC

References

    1. Gupta R, Woodley DT, Chen M. Epidermolysis bullosa acquisita. Clin Dermatol. 2012;30(1):60–69. doi: 10.1016/j.clindermatol.2011.03.011. - DOI - PMC - PubMed
    1. Prost-Squarcioni C., Caux F., Schmidt E., et al. International Bullous Diseases Group: consensus on diagnostic criteria for epidermolysis bullosa acquisita. Br J Dermatol. 2018;179(1):30–41. doi: 10.1111/bjd.16138. - DOI - PubMed
    1. Iwata H., Vorobyev A., Koga H., et al. Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients. Orphanet J Rare Dis. 2018;13(1):153. doi: 10.1186/s13023-018-0896-1. - DOI - PMC - PubMed
    1. Bratsos SP, Demir Z, Mee JB, Groves RW, Tull TJ. Efficacy of rituximab in the treatment of epidermolysis bullosa acquisita. Clin Exp Dermatol. 2024;50(1):97–103. doi: 10.1093/ced/llae283. - DOI - PubMed
    1. Clarke B., Yates M., Adas M., Bechman K., Galloway J. The safety of JAK-1 inhibitors. Rheumatology (Oxford) 2021;60(Suppl 2):ii24–ii30. doi: 10.1093/rheumatology/keaa895. - DOI - PMC - PubMed

Publication types

LinkOut - more resources